Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. - Shah, Manish A.; Wainberg, Zev A.; Catenacci, Daniel V. T.; Hochster, Howard S.; Ford, James; Kunz, Pamela; Lee, Fa-Chyi; Kallender, Howard; Cecchi, Fabiola; Rabe, Daniel C.; Keer, Harold; Martin, Anne-Marie; et al. (PLoS ONE, 2022)